BTIG raised its price target for Biodesix (NASDAQ:BDSX) to $17 from $10, saying “performance this year should restore investor confidence.” The stock closed at $1.61 on April 14. Analyst Sung Ji Nam writes that the...
BTIG initiated coverage of Graphite Bio (NASDAQ:GRPH) with a “buy” rating and price target of $18. The stock closed at $4.15 on April 13. “We believe Graphite Bio’s homology directed repair technology platform...
Cantor Fitzgerald launched coverage of Alpha Tau Medical (NASADQ:DRTS) with an “overweight” rating and $20 price target. The stock closed at $10.58 on April 13. Alpha Tau, which went public in March 2022, is a medical...
Maxim Group launched coverage of Synaptogenix (NASDAQ:SNPX) with a “buy” rating and price target of $14. The stock closed at $7.03 on April 11. Synaptogenix, formerly Neurotrope, is continuing development of bryostatin...
H.C. Wainwright initiated coverage of Syndax Pharmaceuticals (NASDAQ:SNDX) with a “buy” rating and $31 price target. The stock closed at $17.51 on April 8. Syndax is a clinical-stage biopharmaceutical company focused on...
Dawson James halved its price target for Dyadic International (NASDAQ:DYAI) to $3 from $6, citing the company’s C1 platform and whether it will be adopted by a major vaccine maker anytime soon. The stock closed at $2.48...
Maxim Group downgraded Agile Therapeutics (NASDAQ:AGRX) to “hold” from “buy” and removed its price target, citing a financing overhang. The stock closed at 16 cents on April 7. Analyst Naz Rahman writes that Agile ended...
Cantor Fitzgerald analyst Ross Osborn assumed coverage of SI-BONE (NASDAQ:SIBN) with an “overweight” rating and price target of $34. The stock closed at $21.28 April 6. SI-BONE is a medical device company that...
BTIG initiated coverage of Gracell Biotechnologies (NASDAQ:GRCL) with a “buy” rating and $18 price target, “with upside potential driven by value inflection points in the next 12-to-24 months.” The stock closed at $2.33...
Analysts for H.C. Wainwright and SVB Leerink downgraded Silverback Therapeutics (NASDAQ:SBTX) after the company discontinued two leading oncology programs. The stock closed at $3.21 on April 1. The company discontinued...
Cantor Fitzgerald downgraded Akebia Therapeutics (NASDAQ:AKBA) to “neutral” from “overweight” and slashed its price target to $1 from $6 after the company received a complete response letter in response to the NDA for...
Maxim Group reduced its price target for Ayala Pharmaceuticals (NASDAQ:AYLA) to $12 from $22, but maintained a “buy” rating, after the company discontinued the Phase 2 TENANCITY trial evaluating AL101 in triple negative...
Alliance Global Partners slashed its price target for ReShape Lifesciences (NASDAQ:RSLS) to $5.50 from $10.25 but maintained its “buy” rating, citing the company’s fourth quarter results. The stock closed at $1.35 on...
Stifel downgraded MEI Pharma (NASDAQ:MEIP) to “hold” from “buy” and reduced its price target to $2 from $6 after the FDA discouraged a regulatory filing based on single-arm Phase 2 TIDAL study data, despite previous...
Maxim Group initiated coverage of Longeveron (NASDAQ:LGVN) with a “buy” rating and $14 price target. The stock closed at $6.52 on March 23. Longeveron is developing a medicinal signaling cell therapy, Lomecel-B, for...
Maxim Group initiated coverage of HCW Biologics (NASDAQ:HCWB) with a “buy” rating and price target of $4. The stock closed at $2.28 on March 23. HCW Biologics is addressing inflammaging; the chronic, sterile, low-grade...
H.C. Wainwright launched coverage of BioAtla (NASDAQ:BCAB) with a “buy” rating and $25 price target. The stock closed at $5.77 on March 18. BioAtla is a clinical-stage biopharmaceutical company developing novel...
BTIG downgraded Talis Biomedical (NASDAQ:TLIS) to “sell” from “neutral” with a price target of $1, citing a delay in the beta-phase rollout of the Talis One COVID-19 diagnostic, which was planned for the first quarter...
Raymond James downgraded Cardiol Therapeutics (TSX:CRDL) to “market perform” from “outperform” and trimmed its price target to $4 (Canadian) from $5, citing a slower than expected enrollment in Cardiol’s LANCER clinical...
Maxim Group initiated coverage of Unicycive Therapeutics (NASDAQ:UNCY) with a “buy” rating and price target of $3. The stock closed at $1.07 on March 15. Unicycive is aiming to bring two key assets through clinical...
SVB Leerink launched coverage of Pardes Biosciences (NASDAQ:PRDS) with an “outperform” rating and $18 price target. The stock closed at $5.54 on March 14. Pardes is a clinical-stage biopharmaceutical company created to...
H.C. Wainwright initiated coverage of Esperion Therapeutics (NASDAQ:ESPR) with a “buy” rating and price target of $22. The stock closed at $4.57 on March 9. Esperion is a commercial-stage company focused on development...